Yu Peng Li
Directeur/Membre du Conseil chez MabPlex International Co., Ltd.
Profil
Yu Peng Li currently works at MabPlex International Co., Ltd., as Member-Supervisory Board from 2019.
Mr. Li also formerly worked at Beijing Biostar Pharmaceuticals Co. Ltd., as Director from 2020 to 2023.
Mr. Li received his graduate degree in 2011 from Chinese Academy of Fiscal Sciences.
Postes actifs de Yu Peng Li
| Sociétés | Poste | Début |
|---|---|---|
MabPlex International Co., Ltd.
 MabPlex International Co., Ltd. Pharmaceuticals: MajorHealth Technology MabPlex International Co., Ltd. engages in the provision of contract development and manufacturing organization (CDMO) services in the biopharmaceutical field. It provides CDMO services for monoclonal antibodies, double antibodies, polyclonal antibodies, fusion proteins, antibody-drug conjugates, recombinant vaccines, recombinant proteins, and other biological drugs; and cell culture medium. The company was founded by Jan Min Fang on June 25, 2013 and is headquartered in Yantai, China. | Directeur/Membre du Conseil | 01/12/2019 |
Anciens postes connus de Yu Peng Li
| Sociétés | Poste | Fin |
|---|---|---|
Beijing Biostar Pharmaceuticals Co. Ltd.
 Beijing Biostar Pharmaceuticals Co. Ltd. Pharmaceuticals: MajorHealth Technology Beijing Biostar Pharmaceuticals Co. Ltd. engages in the tumor treatment. The company focuses on the development of new anti-cancer drugs with independent intellectual property rights. Its product Utidelone injection is the new-generation microtubule inhibitor produced by microbial fermentation process. The company was founded by Li Tang and Rong Guo Qiu on July 11, 2002 and is headquartered in Beijing, China. | Directeur/Membre du Conseil | 01/12/2023 |
Formation de Yu Peng Li
| Chinese Academy of Fiscal Sciences | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Beijing Biostar Pharmaceuticals Co. Ltd.
Beijing Biostar Pharmaceuticals Co. Ltd. Pharmaceuticals: MajorHealth Technology Beijing Biostar Pharmaceuticals Co. Ltd. engages in the tumor treatment. The company focuses on the development of new anti-cancer drugs with independent intellectual property rights. Its product Utidelone injection is the new-generation microtubule inhibitor produced by microbial fermentation process. The company was founded by Li Tang and Rong Guo Qiu on July 11, 2002 and is headquartered in Beijing, China. | Health Technology |
MabPlex International Co., Ltd.
MabPlex International Co., Ltd. Pharmaceuticals: MajorHealth Technology MabPlex International Co., Ltd. engages in the provision of contract development and manufacturing organization (CDMO) services in the biopharmaceutical field. It provides CDMO services for monoclonal antibodies, double antibodies, polyclonal antibodies, fusion proteins, antibody-drug conjugates, recombinant vaccines, recombinant proteins, and other biological drugs; and cell culture medium. The company was founded by Jan Min Fang on June 25, 2013 and is headquartered in Yantai, China. | Health Technology |